What is the signal?
Circana's U.S. beauty retail release of 12 November 2026 covers year-to-date performance through September. Prestige retail reached $25.5 billion, up 5% on the same period last year, and mass retail reached $57.4 billion, up 7%. Within prestige, skincare at $7.4 billion (7%) and hair care at $3.7 billion (7%) tied as the top dollar-growth categories, while fragrance grew 5% to $6.2 billion and makeup 3% to $8.1 billion. In mass, fragrance dollars rose 15%, skincare close to 8%, hair close to 6% and cosmetics more than 4%.
On dollars alone this is ordinary growth, but units change its character. In prestige, unit sales across the major categories were up on the previous year, and skincare's unit growth was in double digits. If dollars rose 7% while units rose double digits, the average selling price per unit fell. In mass, units were slightly higher and that gain came mainly from skincare and fragrance. U.S. skincare, in other words, is not a market that grew by selling at higher prices; it grew by selling more units.
Circana reads it the same way. Circana's Larissa Jensen attributed the skincare rebound partly to 2025 having been a relatively soft year for the category and partly to rising interest in devices, K-beauty treatments and serums. She explained beauty's outperformance against many discretionary industries by noting that consumers see these products as both functional and emotionally rewarding. On the fourth quarter she said it will be defined by selective splurging, and expects consumers to keep seeking value through promotions, cross-channel shopping and more affordable alternatives. One-third of consumers plan to buy a beauty product as a holiday gift, and Circana expects fragrance, prestige skincare and gift sets to be popular gifting items.
The practical signal we read in these figures is single. Demand for skincare in the U.S. is rising, but the price point that demand reaches is coming down. When demand grows while the amount collectable per unit falls, what a product has to clear is not the sophistication of its formula but its cost structure. Fill size, container, production quantity and the scope of the evidence supporting efficacy are all derived backwards from the price point.
Four limits apply when reading this. First, these are cumulative figures through September, so the fourth quarter and the year-end peak are not in them; Jensen's fourth-quarter remarks are a forecast, not a measurement. Second, Circana's figures track specific retail channels, and which channels and accounts are included cannot be confirmed from this release alone, so how brand-owned stores and routes outside the panel are reflected needs separate checking. Third, these are category-level numbers, so which items at which price points drove the unit gains is not in the release. Fourth, interest in K-beauty treatments is an item Circana cited as a growth factor, not a measured share. The development reading below is our interpretation of these numbers, not a forecast that U.S. price points will keep falling.
1. When units outrun dollars, it is a size-design problem
Units growing faster than dollars is produced one of two ways: cheaper products sold, or the same product sold in smaller units. Either way the item a brand has to touch is the same — the size of one unit and the price of that unit. It is not a job of changing ingredients but of deciding how to cut one unit.
Shrinking the fill, however, does not cut cost proportionally. Bulk cost falls with volume, but container, components, label, carton and packing labour attach per unit. Take a 50 ml down to 30 ml and the bulk drops 40% while total cost does not, so cost per millilitre actually rises. A strategy of lowering the price point through a smaller size only holds once you have calculated how far the fixed cost per unit can come down.
Deriving the size backwards from the price point is therefore safer. Reverse the order — fix format and fill first, then try to meet a price — and the revisions that arrive late in development are swapping to a cheaper container or lowering the active content. Late revisions often require stability testing again, so schedule and cost rise together.
When carrying several sizes, giving each a different job reads more clearly. The small size is where someone tries the product; the large size is where they buy it again. Price both at the same cost per millilitre and there is no reason to buy the large one; widen the gap too far and the small one looks expensive. That interval is a marketing judgement, but it bears directly on container specification and production quantity, so it belongs in the meeting that freezes the formula.
It also affects quantity planning. Split into two sizes and you have two SKUs, each with its own container tooling, label, stability data and minimum production quantity. COSLAB consults on projects from 1,000 units upward, and what is actually feasible depends on the formula, container, raw materials, process and specification. It is worth reflecting in the quantity plan, up front, that a decision to add a size is a decision to add an SKU.
- Whether the target consumer price was fixed first and the fill size derived from it
- Whether costs that attach per unit — container, components, packing labour — were calculated separately
- Whether the small and large sizes were given different jobs (trial and repurchase)
- Whether the quantity plan reflects that splitting sizes raises SKU count and minimum production quantity
2. The cited growth factors include K-beauty treatments and serums
What Jensen named as factors in the skincare rebound were devices, K-beauty treatments and serums. For a brand developing in Korea, those three words point to one shared condition: not the basic step used every day, but a product used as one additional step for a specific purpose. Serums, ampoules, masks and pads — the added step — are the segment adding units in the U.S.
Added-step products make different development demands. For a basic lotion what matters is not disturbing the overall state of the skin, but an added-step product has to have its reason for use stated in one sentence, and that sentence becomes the criterion for the formula. The type and level of actives, the format that aids delivery, frequency of use and compatibility with the steps used alongside all follow from it. Put in two or more purposes and the formula gets more complex while the explanation gets weaker.
Demand for use alongside a device also changes development conditions. A product used with a device faces different conditions of applied amount, duration, friction and conductivity than one applied by hand only. If device use is assumed, those conditions belong in the use-test design, and use without the device has to be covered too. Our judgement is that confirming a format that holds under both conditions comes before writing device compatibility into the specification.
Treat the favourable position of Korean origin as fact, but we would not recommend using it as the content of the product. What Circana noted was an increase in interest, and what competes on a U.S. shelf is ultimately another serum at the same price. Origin opens the door you come in through; the reason to buy again is made by the product.
Format choice has to account for U.S. distribution conditions too. Serums and ampoules are small and ship efficiently, while bulky, heavy items such as pads and sheet masks carry a far larger share of logistics cost per unit. In a market growing on unit volume, that share constrains price-point design directly.
- Whether the reason to use the product fits in one sentence (one purpose)
- Whether active type, level, frequency and compatible steps were derived from that sentence
- Whether both use with a device and use by hand alone were confirmed
- Whether the effect of volume and weight on logistics cost per unit and price point was calculated
3. Where mass grows faster than prestige, the price point decides the channel
In the same release mass retail grew 7% against prestige at 5%. Mass fragrance dollars rose 15% and mass skincare close to 8%. Circana expects consumers to keep seeking value through promotions, cross-channel shopping and more affordable alternatives — meaning demand at lower price points does not stay inside one channel.
For a brand this changes one step in the order. The common sequence has been to make the product and then decide which channel it goes into. In a market where the price point divides demand, the target price point is settled first, that price point settles which channels it can enter, and the channel's requirements settle formula, container and quantity — because barcode and label formats, pack units, delivery lead times and minimum order quantities differ by channel.
Trying to cover several price points with one formula usually comes back as cost. Put the same bulk in a different container at a different price and consumers across the two channels do not take long to notice it is the same product. Make a separate formula per price point, on the other hand, and development cost, stability testing and the number of SKUs to manage all double. For a first launch it reads more clearly to pick one price point and make the product whose explanation is clearest at that price.
Price design has to assume promotion as well. Discounting and set bundling are close to a standing condition in U.S. beauty retail. Enter with a cost structure that only works at list price and the first promotion erases the margin. Setting a cost ceiling that assumes a discount depth and a set configuration before the formula is frozen avoids later revisions that take ingredients out.
Set configuration belongs with the SKU plan. Circana expects gift sets to be popular for the holidays. A set is a new SKU, and a new SKU carries its own packaging specification, production quantity and label copy. Schedule it as merely bundling singles and you hit a wall when the packaging components have to be ordered.
- Whether the order was changed to fix the price point, then the channel, then the specification
- Whether the first launch was cut to a single price point
- Whether a cost ceiling assuming discounts and sets was set before formulation freeze
- Whether sets were planned as separate SKUs with their own packaging, quantity and labelling
4. Where efficacy sells, the evidence is part of the product
If the segment adding units is serums and treatments, the reason for purchase is an expectation of efficacy. Products bought on that expectation are not explained by wording but by evidence. Wording used without evidence is a weak point in channel review, in consumer enquiries and in competitor complaints alike. Which evidence to secure, and to what level, is therefore a development schedule item rather than a marketing decision.
Evidence varies widely in cost and duration by type. Raw-material studies supplied by the ingredient maker, usability assessments run on the finished product, and human studies with instrumental measurement each permit a different range of statements. Claiming an effect for the finished product on the basis of a raw-material study puts claim and evidence out of alignment. It is more realistic to pick the one claim the first launch genuinely needs and design only the study that supports it.
The permitted range of wording differs by market. The same sentence can be usable in Korea and change the product's classification in the U.S. Change the classification and the required evidence and manufacturing conditions change with it, which is a revision that travels back to the formulation stage. Fixing the launch markets before formulation freeze, and choosing the claims to be used in those markets first, reduces revisions that travel backwards.
The validity period of evidence has to be managed as a specification too. Change the formula and the test results obtained on the previous formula are no longer that product's evidence. When a revision to meet cost changes the active level or the base, the decision of whether to obtain evidence again on the revised formula or to narrow the claim has to be made there and then. Defer it and the product launches with evidence and label out of alignment.
Settle storage as well. Unless it is decided where and in what format test reports, raw-material specifications and test conditions are kept, every channel or distributor request means assembling the file from scratch. That cost multiplies by the number of SKUs as the range grows.
- Whether one claim was chosen for the first launch and only the matching study designed
- Whether the scope of raw-material studies and finished-product testing was kept distinct
- Whether the launch market's permitted wording was checked before formulation freeze
- Whether there is a rule for formula changes: obtain evidence again, or narrow the claim
- Whether the storage location and format for test reports and raw-material specifications were decided
5. What these numbers can settle, and what they cannot
What this release can settle is direction: that U.S. skincare demand is rising, that a substantial part of the growth is coming from units rather than dollars, and that interest is gathering around added-step products — serums and treatments — and around devices. That direction supports fixing the price point first and deriving size and specification from it.
What it cannot settle is the numbers. Which price points sold how much, which items drove the unit gains, and how much of that was Korean-made are not in this release. Whether to target a given dollar price, or a given fill in millilitres, is a value to set from the actual shelf prices and competing items in your first launch channel, not from this panel.
Keep the fourth-quarter outlook separate from the measurement as well. The remarks on selective splurging and gifting demand are Circana's expectations; the actual results arrive in a later release. Decide SKUs for the year-end peak on a forecast alone and what remains when the forecast misses is inventory.
There are three things to watch: whether skincare unit growth again outruns dollar growth in the next release, whether the growth gap between mass and prestige widens or narrows, and whether the interest in devices and treatments Circana cited shows up in subcategory numbers. The third is the most practical. Subcategory figures would show which formats within the added step demand concentrated on.
Until then the task is not waiting for numbers. Fixing the target price point, calculating the cost ceiling per unit that holds at that price, and confirming which containers and active ranges are usable inside that ceiling is work that stands however the next release turns out.
- Whether this release was used for direction only, with target price and fill set from real shelf prices
- Whether the fourth-quarter forecast and the results through September were written down separately
- Whether the indicators to check in the next release were chosen (units vs dollars, channel gap, subcategories)
- Whether the work that stands regardless — cost ceiling, container, active range — was finished first
The first question for the brief
Delete the line that reads "U.S. skincare market growth" and write two instead. The first is price: write as a single number the consumer price this product will carry on the shelf in your first launch channel, and the cost ceiling per unit derived from it. The second is the size of one unit that follows from that ceiling: confirm that fill, container, components and pack unit can be met inside it before freezing the format.
Next write the pair of claim and evidence. Put the one sentence explaining why someone uses this product and the one study supporting that sentence on the same line, and it becomes clear what can be conceded when a cost revision arrives. Widening claims first and fitting evidence afterwards is almost always expensive.
The last line is the condition for expansion. Note that adding one more size, or opening one more price point, adds not only inventory but SKUs, minimum production quantities, packaging specifications and files of evidence to maintain. The most useful single line to add to the brief today is at what price and in what fill one unit of this product is cut, and who confirms that decision, and when.
Sources
- Beauty Industry Maintains Momentum as U.S. Consumers Balance Self-Indulgence and Value Seeking Ahead of the Holiday Season — Circana, 2026-11-12
- Beauty Industry Maintains Momentum as U.S. Consumers Balance Self-Indulgence and Value Seeking Ahead of the Holiday Season — GlobeNewswire, 2026-11-12
- How Did Beauty Perform During the Third Quarter of 2026? — WWD
For more context, see the product development guide and MOQ 1,000 guide.